Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.03
COO's Cash to Debt is ranked lower than
99% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. COO: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
COO' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.04 Max: 1.92
Current: 0.03
0
1.92
Equity to Asset 0.60
COO's Equity to Asset is ranked higher than
52% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. COO: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
COO' s Equity to Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.59 Max: 0.8
Current: 0.6
0.07
0.8
Interest Coverage 10.73
COO's Interest Coverage is ranked lower than
67% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.93 vs. COO: 10.73 )
Ranked among companies with meaningful Interest Coverage only.
COO' s Interest Coverage Range Over the Past 10 Years
Min: 1.07  Med: 9.13 Max: 38.48
Current: 10.73
1.07
38.48
F-Score: 5
Z-Score: 4.17
M-Score: -2.55
WACC vs ROIC
4.74%
5.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.96
COO's Operating margin (%) is ranked higher than
72% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. COO: 12.96 )
Ranked among companies with meaningful Operating margin (%) only.
COO' s Operating margin (%) Range Over the Past 10 Years
Min: 4.82  Med: 15.13 Max: 19.61
Current: 12.96
4.82
19.61
Net-margin (%) 11.19
COO's Net-margin (%) is ranked higher than
78% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. COO: 11.19 )
Ranked among companies with meaningful Net-margin (%) only.
COO' s Net-margin (%) Range Over the Past 10 Years
Min: -1.18  Med: 10.54 Max: 18.65
Current: 11.19
-1.18
18.65
ROE (%) 7.78
COO's ROE (%) is ranked higher than
58% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.61 vs. COO: 7.78 )
Ranked among companies with meaningful ROE (%) only.
COO' s ROE (%) Range Over the Past 10 Years
Min: -0.79  Med: 7.4 Max: 12.88
Current: 7.78
-0.79
12.88
ROA (%) 4.65
COO's ROA (%) is ranked higher than
61% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. COO: 4.65 )
Ranked among companies with meaningful ROA (%) only.
COO' s ROA (%) Range Over the Past 10 Years
Min: -0.45  Med: 4.5 Max: 9.74
Current: 4.65
-0.45
9.74
ROC (Joel Greenblatt) (%) 15.96
COO's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.27 vs. COO: 15.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
COO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.39  Med: 17.35 Max: 29.5
Current: 15.96
5.39
29.5
Revenue Growth (3Y)(%) 7.50
COO's Revenue Growth (3Y)(%) is ranked higher than
63% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. COO: 7.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
COO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.4  Med: 13.4 Max: 27.9
Current: 7.5
5.4
27.9
EBITDA Growth (3Y)(%) 2.20
COO's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. COO: 2.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
COO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 16.1 Max: 62.2
Current: 2.2
-8.6
62.2
EPS Growth (3Y)(%) -6.40
COO's EPS Growth (3Y)(%) is ranked lower than
68% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. COO: -6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
COO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.2  Med: 14.9 Max: 36.4
Current: -6.4
-15.2
36.4
» COO's 10-Y Financials

Financials (Next Earnings Date: 2016-09-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

COO Guru Trades in Q3 2015

Paul Tudor Jones 3,231 sh (New)
Pioneer Investments 27,668 sh (New)
Ray Dalio 2,897 sh (New)
Jim Simons 114,004 sh (+268.97%)
Ken Fisher 92,583 sh (+18.19%)
David Carlson 190,000 sh (unchged)
Mario Gabelli 28,500 sh (unchged)
Andreas Halvorsen Sold Out
Ron Baron 334,134 sh (-2.93%)
» More
Q4 2015

COO Guru Trades in Q4 2015

George Soros 6,500 sh (New)
Jim Simons 132,198 sh (+15.96%)
David Carlson 210,000 sh (+10.53%)
Ken Fisher 93,854 sh (+1.37%)
Mario Gabelli 28,500 sh (unchged)
Samuel Isaly 205,000 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
Ron Baron 243,262 sh (-27.20%)
» More
Q1 2016

COO Guru Trades in Q1 2016

Manning & Napier Advisors, Inc 600,385 sh (New)
Paul Tudor Jones 1,662 sh (New)
Steven Cohen 46,500 sh (New)
Ron Baron 270,063 sh (+11.02%)
Mario Gabelli 28,500 sh (unchged)
David Carlson 210,000 sh (unchged)
Samuel Isaly 205,000 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Ken Fisher 93,114 sh (-0.79%)
» More
Q2 2016

COO Guru Trades in Q2 2016

Steven Cohen 268,400 sh (+477.20%)
Paul Tudor Jones 3,355 sh (+101.87%)
Ken Fisher 106,914 sh (+14.82%)
Ron Baron 270,131 sh (+0.03%)
David Carlson 210,000 sh (unchged)
Mario Gabelli 28,500 sh (unchged)
Samuel Isaly 205,000 sh (unchged)
Manning & Napier Advisors, Inc 562,995 sh (-6.23%)
» More
» Details

Insider Trades

Latest Guru Trades with COO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:RMD, NAS:HOLX, NYSE:MTD, OTCPK:OCPNY, OTCPK:SAUHF, NAS:SIRO, NYSE:STE, NYSE:WST, OTCPK:GNGBY, NYSE:WAT, NYSE:HRC, NAS:XRAY, NYSE:CMN, OTCPK:ANSLF, NAS:PODD, NAS:ICUI, OTCPK:TRUMF, NYSE:HAE, NYSE:BCR, NYSE:HYH » details
Traded in other countries:CP6.Germany, COO.Mexico,
The Cooper Companies Inc is a medical device company. Through its subsidiaries, it manufactures products for contact lens wearers and supplies women's health clinicians with products and treatment options to improve the delivery of healthcare to women.

The Cooper Companies Inc is a Delaware corporation, which was organized on March 4, 1980. It is a medical device company. Through its subsidiaries, it manufactures products for contact lens wearers and supplies women's health clinicians with products and treatment options to improve the delivery of healthcare to women. It develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring materials and optics. It products are designed to solve vision challenges such as astigmatism, presbyopia and ocular dryness; with a broad collection of spherical, toric and multifocal contact lenses. The Company's customers are healthcare professionals and institutions providing care to and for women. Its products support the point of healthcare delivery in the hospital, clinician's office and fertility clinics. The Company's manufacturing and distribution facilities are located in Trumbull, Connecticut, Malov, Denmark, Pasadena, California, Stafford, Texas, and Berlin, Germany. The Company's raw materials consist of various chemicals and packaging materials and are generally available from more than one source. It markets its products in the United States through field sales representatives, who call on optometrists, ophthalmologists, opticians, optical chains and distributors. The Company's products are medical devices subject to extensive regulation by the United States Food and Drug Administration (FDA) in the United States and other regulatory bodies abroad.

Guru Investment Theses on The Cooper Companies Inc

Baron Funds Comments on The Cooper Companies - Jan 26, 2016

Shares of The Cooper Companies, Inc. (NYSE:COO), a global contact lens manufacturer, fell after its earnings fell short of Wall Street expectations. Results were negatively impacted by missteps in integrating its recent acquisition of Sauflon Pharmaceuticals Ltd., a British contact lens company, as well as fallout from new competitive lenses. Management projected moderating market share gains and lowered the company’s targeted five-year growth rate. Although disappointed, we remain cautiously optimistic, given Cooper’s reduced valuation and our belief that its revised earnings targets are achievable. Furthermore, we believe that shifts in the contact lens market toward greater adoption of silicon hydrogel lenses and daily modalities will play to Cooper’s strengths.



From Baron Funds' Baron Asset Fund commentary for fourth quarter 2015.



Check out Ron Baron latest stock trades

Top Ranked Articles about The Cooper Companies Inc

Baron Funds Comments on The Cooper Companies Guru stock highlight
Shares of The Cooper Companies, Inc. (NYSE:COO), a global contact lens manufacturer, fell after its earnings fell short of Wall Street expectations. Results were negatively impacted by missteps in integrating its recent acquisition of Sauflon Pharmaceuticals Ltd., a British contact lens company, as well as fallout from new competitive lenses. Management projected moderating market share gains and lowered the company’s targeted five-year growth rate. Although disappointed, we remain cautiously optimistic, given Cooper’s reduced valuation and our belief that its revised earnings targets are achievable. Furthermore, we believe that shifts in the contact lens market toward greater adoption of silicon hydrogel lenses and daily modalities will play to Cooper’s strengths. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 43.69
COO's P/E(ttm) is ranked lower than
74% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.11 vs. COO: 43.69 )
Ranked among companies with meaningful P/E(ttm) only.
COO' s P/E(ttm) Range Over the Past 10 Years
Min: 8.06  Med: 22.37 Max: 1011.75
Current: 43.69
8.06
1011.75
Forward P/E 19.53
COO's Forward P/E is ranked higher than
77% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.83 vs. COO: 19.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 43.69
COO's PE(NRI) is ranked lower than
75% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.42 vs. COO: 43.69 )
Ranked among companies with meaningful PE(NRI) only.
COO' s PE(NRI) Range Over the Past 10 Years
Min: 8.06  Med: 22.37 Max: 1011.75
Current: 43.69
8.06
1011.75
Price/Owner Earnings (ttm) 46.79
COO's Price/Owner Earnings (ttm) is ranked lower than
74% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.70 vs. COO: 46.79 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
COO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.85  Med: 23.8 Max: 195
Current: 46.79
13.85
195
P/B 3.26
COO's P/B is ranked lower than
52% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. COO: 3.26 )
Ranked among companies with meaningful P/B only.
COO' s P/B Range Over the Past 10 Years
Min: 0.37  Med: 1.82 Max: 3.62
Current: 3.26
0.37
3.62
P/S 4.90
COO's P/S is ranked lower than
68% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. COO: 4.90 )
Ranked among companies with meaningful P/S only.
COO' s P/S Range Over the Past 10 Years
Min: 0.51  Med: 2.84 Max: 5.22
Current: 4.9
0.51
5.22
PFCF 51.17
COO's PFCF is ranked lower than
80% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.51 vs. COO: 51.17 )
Ranked among companies with meaningful PFCF only.
COO' s PFCF Range Over the Past 10 Years
Min: 7.33  Med: 26.52 Max: 353.03
Current: 51.17
7.33
353.03
POCF 23.36
COO's POCF is ranked lower than
70% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.48 vs. COO: 23.36 )
Ranked among companies with meaningful POCF only.
COO' s POCF Range Over the Past 10 Years
Min: 5.63  Med: 14.55 Max: 23.53
Current: 23.36
5.63
23.53
EV-to-EBIT 43.73
COO's EV-to-EBIT is ranked lower than
79% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.49 vs. COO: 43.73 )
Ranked among companies with meaningful EV-to-EBIT only.
COO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 21.15 Max: 72
Current: 43.73
11.4
72
EV-to-EBITDA 23.45
COO's EV-to-EBITDA is ranked lower than
70% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.12 vs. COO: 23.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
COO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.9  Med: 14.9 Max: 24.4
Current: 23.45
6.9
24.4
PEG 4.22
COO's PEG is ranked lower than
72% of the 61 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. COO: 4.22 )
Ranked among companies with meaningful PEG only.
COO' s PEG Range Over the Past 10 Years
Min: 0.78  Med: 1.99 Max: 22.9
Current: 4.22
0.78
22.9
Shiller P/E 52.69
COO's Shiller P/E is ranked lower than
67% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.84 vs. COO: 52.69 )
Ranked among companies with meaningful Shiller P/E only.
COO' s Shiller P/E Range Over the Past 10 Years
Min: 7.07  Med: 33.83 Max: 60.08
Current: 52.69
7.07
60.08
Current Ratio 2.84
COO's Current Ratio is ranked higher than
57% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. COO: 2.84 )
Ranked among companies with meaningful Current Ratio only.
COO' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 2.16 Max: 3.46
Current: 2.84
0.98
3.46
Quick Ratio 1.49
COO's Quick Ratio is ranked lower than
58% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. COO: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
COO' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.22 Max: 2.95
Current: 1.49
0.69
2.95
Days Inventory 199.96
COO's Days Inventory is ranked lower than
77% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.07 vs. COO: 199.96 )
Ranked among companies with meaningful Days Inventory only.
COO' s Days Inventory Range Over the Past 10 Years
Min: 167.05  Med: 207.61 Max: 231.4
Current: 199.96
167.05
231.4
Days Sales Outstanding 58.94
COO's Days Sales Outstanding is ranked higher than
56% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. COO: 58.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
COO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.77  Med: 58.81 Max: 63.16
Current: 58.94
52.77
63.16
Days Payable 50.53
COO's Days Payable is ranked higher than
50% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.53 vs. COO: 50.53 )
Ranked among companies with meaningful Days Payable only.
COO' s Days Payable Range Over the Past 10 Years
Min: 27.82  Med: 55.91 Max: 72.43
Current: 50.53
27.82
72.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.03
COO's Dividend Yield is ranked lower than
100% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. COO: 0.03 )
Ranked among companies with meaningful Dividend Yield only.
COO' s Dividend Yield Range Over the Past 10 Years
Min: 0.03  Med: 0.09 Max: 0.52
Current: 0.03
0.03
0.52
Dividend Payout 0.01
COO's Dividend Payout is ranked higher than
99% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.33 vs. COO: 0.01 )
Ranked among companies with meaningful Dividend Payout only.
COO' s Dividend Payout Range Over the Past 10 Years
Min: 0.01  Med: 0.04 Max: 0.25
Current: 0.01
0.01
0.25
Forward Dividend Yield 0.03
COO's Forward Dividend Yield is ranked lower than
100% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. COO: 0.03 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.03
COO's Yield on cost (5-Year) is ranked lower than
99% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. COO: 0.03 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
COO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.03  Med: 0.09 Max: 0.52
Current: 0.03
0.03
0.52
3-Year Average Share Buyback Ratio 0.10
COO's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. COO: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
COO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.9  Med: -1.6 Max: 1.2
Current: 0.1
-12.9
1.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 132.16
COO's Price/Tangible Book is ranked lower than
99% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. COO: 132.16 )
Ranked among companies with meaningful Price/Tangible Book only.
COO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.27  Med: 8.75 Max: 1768
Current: 132.16
3.27
1768
Price/Projected FCF 1.95
COO's Price/Projected FCF is ranked higher than
51% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. COO: 1.95 )
Ranked among companies with meaningful Price/Projected FCF only.
COO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.62 Max: 5.86
Current: 1.95
0.57
5.86
Price/DCF (Earnings Based) 4.09
COO's Price/DCF (Earnings Based) is ranked lower than
82% of the 17 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. COO: 4.09 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.73
COO's Price/Median PS Value is ranked lower than
79% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. COO: 1.73 )
Ranked among companies with meaningful Price/Median PS Value only.
COO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.01 Max: 2.6
Current: 1.73
0.26
2.6
Price/Peter Lynch Fair Value 6.22
COO's Price/Peter Lynch Fair Value is ranked lower than
95% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.35 vs. COO: 6.22 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
COO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.6  Med: 1.36 Max: 70
Current: 6.22
0.6
70
Price/Graham Number 16.03
COO's Price/Graham Number is ranked lower than
99% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. COO: 16.03 )
Ranked among companies with meaningful Price/Graham Number only.
COO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.78  Med: 2.66 Max: 54.57
Current: 16.03
0.78
54.57
Earnings Yield (Greenblatt) (%) 2.28
COO's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. COO: 2.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
COO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 4.7 Max: 8.8
Current: 2.28
1.4
8.8
Forward Rate of Return (Yacktman) (%) 9.37
COO's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.21 vs. COO: 9.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
COO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2  Med: 14.9 Max: 23.1
Current: 9.37
-2
23.1

More Statistics

Revenue (TTM) (Mil) $1,851
EPS (TTM) $ 4.23
Beta0.50
Short Percentage of Float3.98%
52-Week Range $119.28 - 189.76
Shares Outstanding (Mil)48.45

Analyst Estimate

Oct16 Oct17
Revenue (Mil $) 1,950 2,080
EPS ($) 8.27 9.63
EPS w/o NRI ($) 8.27 9.63
EPS Growth Rate
(3Y to 5Y Estimate)
9.83%
Dividends Per Share ($) 0.06 0.07
» More Articles for COO

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlights Jul 06 2016 
Weekly CFO Sells Highlight Jun 13 2016 
Baron Funds Comments on The Cooper Companies Jan 26 2016 
Steve Mandel Buys Visa, DaVita Healthcare In Q4 Feb 19 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Weekly CEO Sells Highlight: Cooper Companies, Broadcom Corp, Realpage Inc, and Freescale Semiconduct Jul 14 2014 
Baron Funds Comments on The Cooper Companies May 02 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Manning & Napier New Buys of Q1 Apr 19 2013 
The Cooper Companies: Not Eyeing It Yet Nov 27 2012 

More From Other Websites
The Cooper Companies to Present at Upcoming Financial Conferences Aug 09 2016
The Cooper Companies to Present at Upcoming Financial Conferences Aug 09 2016
The Cooper Companies Announces Release Date for Third Quarter 2016 Aug 02 2016
The Cooper Companies Announces Release Date for Third Quarter 2016 Aug 02 2016
The Cooper Companies (COO) Scales a New 52-Week High Jul 11 2016
The Cooper Companies Declares Cash Dividend Jul 07 2016
The Cooper Companies Declares Cash Dividend Jul 07 2016
Bill Gates And Other Billionaires Backing A Nuclear Renaissance Jul 06 2016
Weekly CEO Sells Highlights Jul 06 2016
Cooper Companies Strong on Portfolio Expansion Plans Jul 06 2016
CR Bard: Expansion Plans on Track, Product Pipeline Strong Jul 05 2016
Stocks Bounce Back; Netflix Retakes Level As Apple Hits Resistance Jul 01 2016
The Cooper Companies Inc (COO) President & CEO Robert S Weiss Sold $24.8 million of Stocks Jun 29 2016
CooperVision Unveils Biofinity Energys™ Contact Lenses Specifically Designed for Today’s Digital... Jun 29 2016
Weekly CFO Sells Highlight Jun 13 2016
COOPER COMPANIES INC Financials Jun 09 2016
Cooper Cos. Q2 Earnings Beat, As Street Eyes J&J Rival Launch Jun 03 2016
COOPER COMPANIES INC Files SEC form 10-Q, Quarterly Report Jun 03 2016
The Cooper Companies (COO) Beats Q2 Earnings, View Up Jun 03 2016
Edited Transcript of COO earnings conference call or presentation 2-Jun-16 9:00pm GMT Jun 03 2016
Cooper Companies Inc Earnings Call scheduled for 5:00 pm ET today Jun 02 2016
The Cooper Companies Announces Second Quarter 2016 Results Jun 02 2016
COOPER COMPANIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jun 02 2016
The Cooper Companies Announces Second Quarter 2016 Results Jun 02 2016
Q2 2016 Cooper Companies Inc Earnings Release - 4:15 pm ET Jun 02 2016
U.S. Stocks Open June Under Pressure but Fight It Off Jun 01 2016
The Cooper Companies Acquires Assets of Recombine May 25 2016
The Cooper Companies to Present at William Blair Conference May 19 2016
The Cooper Companies to Present at Upcoming Financial Conferences May 17 2016
The Cooper Companies Announces Release Date for Second Quarter 2016 May 04 2016
The Cooper Companies' Women's Health Care Unit Acquires Genesis Genetics Apr 04 2016
The Cooper Companies Appoints William Kozy and Colleen Jay to Board of Directors Apr 04 2016
The Cooper Companies Declares Cash Dividend Jan 07 2016
The Cooper Companies Sets Annual Meeting and Stockholder Record Dates Dec 22 2015
The Cooper Companies' Women's Health Care Unit Acquires Research Instruments Dec 17 2015
The Cooper Companies to Present at J.P. Morgan Healthcare Conference Dec 16 2015
The Cooper Companies Announces Fourth Quarter and Full Year 2015 Results Dec 03 2015
The Cooper Companies to Present at Oppenheimer Conference Nov 24 2015
The Cooper Companies Announces Third Quarter 2015 Results Sep 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)